Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care
• First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential of xevinapant over standard of care in......
最新文章
網石吸血鬼主題MMORPG《VAMPIR:血之繼承者》 將開放全新伺服器「艾利格」以滿足玩家強烈需求
Lightmatter 擴展光子互連產品藍圖,推出 Passage™ L20 通用型光學引擎,支援 NPO 與 OBO 應用
Lightmatter 發表 vClick Optics, 業界首款用於 CPO 先進封裝與量產的可拆式光纖陣列模組 實現可大規模部署且具可維修性的高頻寬 Passage 3D 光子互連
Lightmatter 發表 vClick Optics, 業界首款用於 CPO 先進封裝與量產的可拆式光纖陣列模組 實現可大規模部署且具可維修性的高頻寬 Passage 3D 光子互連
Lightmatter Achieves Record 1.6 Tbps Per Fiber to Accelerate AI Optical Interconnect

